- Nachrichtendetail
-
16.04.2024 13:04:29 - dpa-AFX: *ASTRAZENECA SAYS IMFINZI+CHEMOTHERAPY DOUBLED OVERALL SURVIVAL RATE AT THREE YEARS IN TOPAZ-1 PHASE III TRIAL
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
ASTRAZENECA PLC DL-,25 | 886455 | Xetra | 141,300 | 29.04.24 17:35:38 | +1,000 | +0,71% | 0,000 | 0,000 | 143,050 | 140,300 |
